FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

Epithalon

Epitalon / Epithalone / AEDG peptide

Longevity & Anti-Aging

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action is activation of the enzyme telomerase, which elongates telomeres at the ends of chromosomes, theoretically addressing one of the fundamental mechanisms of cellular aging. It is one of the most researched anti-aging peptides, with over 30 years of study primarily from Russian academic institutions.

作用机制

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase by inducing the catalytic subunit hTERT. Telomerase elongates telomeres, the protective chromosomal endcaps that shorten with each cell division. May slow cellular aging and extend replicative lifespan.

研究协议

仅供研究使用,非医疗建议。

Research protocols use 5-10mg daily via subcutaneous injection for 10-20 day cycles, repeated every 4-6 months. Khavinson protocol: 10mg daily x 10 days, twice yearly.

研究笔记

Clinical Research Status

Epithalon has been studied in multiple clinical settings in Russia, with published data on elderly patients showing improvements in melatonin production, immune function, and cardiovascular parameters. Khavinson's research group published studies spanning over 15 years of follow-up in geriatric cohorts receiving epithalamin/epithalon. However, these studies largely lack the rigorous double-blind placebo-controlled design expected by Western regulatory agencies, and no FDA IND application has been filed.

Key Published Findings

In vitro studies demonstrate that Epithalon activates telomerase in human somatic cells, increasing telomere length and extending cell replicative capacity beyond the Hayflick limit. Animal studies in rodents showed extension of maximum lifespan by 13-25% and reduction in spontaneous tumor incidence. Published human data from Khavinson's group report restoration of melatonin cycling, improved immune markers (T-cell function, thymus recovery), and reduced cardiovascular mortality in elderly patients followed for 6-12 years.

Safety Profile

No significant adverse effects have been reported in published clinical studies spanning decades of use in Russian geriatric populations. The tetrapeptide's small size (4 amino acids) and identity with an endogenous pineal product suggest low immunogenicity and toxicity risk. Animal studies at doses far exceeding therapeutic ranges showed no mutagenic, teratogenic, or carcinogenic effects. The activation of telomerase raises theoretical oncological concerns, though published data paradoxically show reduced tumor incidence.

Drug Interactions & Contraindications

No documented drug interactions exist in published literature. Theoretical concern exists regarding concurrent use with immunosuppressive therapy, as Epithalon may stimulate immune function. The telomerase activation mechanism raises theoretical questions about use in patients with active or recently treated cancers, though available evidence does not support increased cancer risk. Melatonin-modulating effects suggest caution with exogenous melatonin or medications affecting circadian rhythm.

Comparison to Related Compounds

Epithalon is distinguished from other anti-aging peptides (GHK-Cu, BPC-157) by its specific telomerase activation mechanism rather than growth factor or wound healing pathways. Unlike TA-65 (a telomerase activator derived from astragalus), Epithalon is a direct peptide bioregulator rather than a plant extract. Khavinson's broader research program identified tissue-specific bioregulatory peptides for multiple organs (Thymalin for thymus, Cortexin for brain), with Epithalon targeting the pineal-aging axis specifically.

Community Observations

Most commonly administered as 5-10mg subcutaneously daily for 10-20 day cycles, repeated every 4-6 months, following the protocol described in Khavinson's published research. Injectable administration is preferred due to the peptide's small size and potential for GI degradation with oral dosing. Users frequently combine it with other longevity-focused interventions and report improvements in sleep quality, energy levels, and general well-being, though objective telomere measurements are rarely obtained due to cost.

半衰期

~30 minutes

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C up to 24 months.

复溶后

Refrigerate 2-8C. Use within 14 days.

美国法律状态

Research chemical (not FDA-approved)

又称作

EpitalonEpithaloneAEDG peptide

常见问题

什么是 Epithalon?

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland, developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Its primary mechanism of action is activation of the enzyme telomerase, which elongates telomeres at the ends of chromosomes, theoretically addressing one of the fundamental mechanisms of cellular aging. It is one of the most researched anti-aging peptides, with over 30 years of study primarily from Russian academic institutions.

Epithalon 如何起作用?

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase by inducing the catalytic subunit hTERT. Telomerase elongates telomeres, the protective chromosomal endcaps that shorten with each cell division. May slow cellular aging and extend replicative lifespan.

Epithalon 在美国的监管状态是什么?

Research chemical (not FDA-approved)

Epithalon 的半衰期是多少?

~30 minutes

Epithalon 还有哪些名称?

Epitalon, Epithalone, AEDG peptide

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明